logo
logo

Exact sciences licenses targeted digital sequencing; adds leadership in precision oncology

avatar
David Reilly
img
(The Translational Genomics Research Institute) Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has acquired a worldwide exclusive license to the proprietary TARDIS technology from the Translational Genomics Research Institute (TGen), an affiliate of City of Hope. This compelling and technically distinct approach will help expand Exact Sciences' leadership in precision oncology and offers a differentiated patient-specific solution in minimal residual disease testing.
collect
0
avatar
David Reilly
guide
Zupyak is a free content platform for publishing and discovering stories, software and startups.